Compare
ANI Pharmaceuticals Inc vs Madrigal Pharmaceuticals, Inc. vs Corcept Therapeutics Inc vs Emergent BioSolutions Inc.
| Latest fiscal year | ANI Pharmaceuticals Inc ANIP | Madrigal Pharmaceuticals, Inc. MDGL | Corcept Therapeutics Inc CORT | Emergent BioSolutions Inc. EBS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $883.37M | $958.40M | $761.41M | $742.90M |
| Revenue growth (YoY) | +43.8% | +432.1% | +12.8% | -28.8% |
| Gross margin | n/a | n/a | n/a | 56.1% (computed) |
| Operating margin | 12.6% | -31.3% | 5.9% | 13.5% |
| Net margin | 8.9% | -30.1% | 13.1% | 7.1% |
| Net income | $78.34M | -$288.28M | $99.65M | $52.60M |
| EPS (Diluted) | $3.32 | -$12.85 | $0.82 | $0.93 |
| Operating cash flow | $185.22M | -$189.55M | $142.00M | $170.60M |
| Free cash flow | $171.39M | -$190.02M | $141.78M | $156.80M |
| Cash & equivalents | $285.58M | $198.69M | $120.50M | $205.40M |
| Total assets | $1.44B | $1.26B | $836.65M | $1.32B |
| Total liabilities | $899.65M | $656.90M | $188.85M | $796.00M |
| Shareholders' equity | $540.72M | $602.69M | $647.80M | $522.60M |
| Return on year-end equity | 14.5% | -47.8% | 15.4% | 10.1% |
| Shares outstanding | 22.49M | 22.84M | 105.97M | 52.10M |
Revenue, most recent five fiscal years
| Fiscal year | ANI Pharmaceuticals Inc | Madrigal Pharmaceuticals, Inc. | Corcept Therapeutics Inc | Emergent BioSolutions Inc. |
|---|---|---|---|---|
| Latest | $883.37M Ended 2025-12-31 | $958.40M Ended 2025-12-31 | $761.41M Ended 2025-12-31 | $742.90M Ended 2025-12-31 |
| 1 year earlier | $614.38M Ended 2024-12-31 | $180.13M Ended 2024-12-31 | $675.04M Ended 2024-12-31 | $1.04B Ended 2024-12-31 |
| 2 years earlier | $486.82M Ended 2023-12-31 | $0 Ended 2023-12-31 | $482.38M Ended 2023-12-31 | $1.05B Ended 2023-12-31 |
| 3 years earlier | $316.38M Ended 2022-12-31 | $0 Ended 2022-12-31 | $401.86M Ended 2022-12-31 | $1.12B Ended 2022-12-31 |
| 4 years earlier | $216.14M Ended 2021-12-31 | $0 Ended 2021-12-31 | $365.98M Ended 2021-12-31 | $1.77B Ended 2021-12-31 |